Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial

AIMS: To evaluate the safety of up to 3 years of pegaptanib sodium therapy in the treatment of neovascular age-related macular degeneration (NV-AMD). METHODS: Two concurrent, prospective, multicentre, double-masked studies randomised subjects with all angiographic lesion compositions of NV-AMD to re...

Descripción completa

Detalles Bibliográficos
Autores principales: Singerman, L J, Masonson, H, Patel, M, Adamis, A P, Buggage, R, Cunningham, E, Goldbaum, M, Katz, B, Guyer, D
Formato: Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2008
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2584239/
https://www.ncbi.nlm.nih.gov/pubmed/18614570
http://dx.doi.org/10.1136/bjo.2007.132597

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2584239/
https://www.ncbi.nlm.nih.gov/pubmed/18614570
http://dx.doi.org/10.1136/bjo.2007.132597

Ejemplares similares